Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker (Nasdaq: BRKR) appointed Thierry L. Bernard to its Board of Directors effective April 1, 2026. Mr. Bernard is an experienced life‑science tools and diagnostics executive and current CEO of QIAGEN, who has led molecular diagnostics since 2015 and became CEO in 2019.
The company said he will support Bruker’s strategy across life‑science research, biopharma and diagnostics as it pursues profitable growth and margin expansion.
PreOmics and Biognosys (BRKR) announced a favorable PTAB decision: the U.S. Patent Trial and Appeal Board revoked central claims of U.S. Patent No. 11,435,360 (IPR2024-01473), including the sole independent Claim 1.
The patent is owned by The Brigham and Women’s Hospital and exclusively licensed to Seer; the revoked claim covered workflows using multiple nanoparticle types to form biomolecule coronas to detect proteins.
Bruker (Nasdaq: BRKR) launched CellScape XR, a next-generation spatial proteomics platform designed for diagnostic and prognostic assay development. The platform emphasizes quantitative performance, robustness, and high throughput, incorporating advances in optics, fluidics, and protocols to support translational and clinical studies.
Bruker cites collaborations at University Hospital Schleswig-Holstein, Kiel, where teams analyzed >1,000 clinically annotated samples and plan to expand to ~3,000 patient samples, illustrating CellScape XR's intended scalability for large clinical cohorts.
Bruker (Nasdaq: BRKR) is expanding its collaboration with Noetik to scale tissue foundational models using CosMx® Spatial Molecular Imager. The partnership follows a study of >3,500 patient samples and will add thousands more, aiming to train models on up to one billion spatially resolved human cells.
The work targets genome-wide, single-cell and subcellular spatial transcriptomic and multiomic datasets to support translational and therapeutic applications.
Bruker (Nasdaq: BRKR) unveiled major spatial biology product launches and platform upgrades at AGBT 2026, including PaintScape (3D genome visualization), CellScape XR (next‑gen spatial proteomics), CosMx mouse whole transcriptome, expanded GeoMx multiomics, and AtoMx AI‑ready analytics.
Commercial shipments: PaintScape this spring; CellScape XR shipments expected this summer; CosMx mouse WTX early access this spring and full availability later in 2026.
Bruker (Nasdaq: BRKR) announced upgrades to its timsOmni mass spectrometer and ProteoScape, OmniScape, and GlycoScape software on February 23, 2026 to advance "Functional Proteomics 2.0." New features include eXd-enabled glycoproteomics, the OmniWave algorithm for top-down proteoform identification, and AI-enhanced de novo peptide sequencing trained on >7 million spectra for database-independent discovery.
These updates target deeper proteoform and PTM characterization across disease research, immunopeptidomics, metaproteomics, and biotherapeutics analysis.
Bruker (Nasdaq: BRKR) reported Q4-25 revenue of $977.2M (flat yoy; -5.1% organic) and FY25 revenue of $3.44B (+2.1% reported; -3.7% organic). FY25 GAAP loss per share was $(0.15); non-GAAP EPS was $1.83. Bruker guided FY26 revenue to $3.57–3.60B and non-GAAP EPS to $2.10–2.15, noting an ~8% FX headwind to EPS and planned cost savings to expand margins.
Bruker (NYSE:BRKR) launched iNTApharma, a label-free, native-state nanoparticle characterization platform with single-particle sensitivity for viral vectors, LNPs, lentiviral vectors, and extracellular vesicles.
Optimized for particles 50–300 nm, it provides rapid size and concentration measurements, automated well‑plate acquisition, and will be placed with early-access partners in H1 2026 with broader commercial availability in H2 2026.
Chemspeed and SciY (Nasdaq: BRKR) unveiled an open Self‑Driving Lab (SDL) platform on February 9, 2026 at SLAS2026 to unify lab automation, analytics and AI orchestration.
The SDL offers vendor‑agnostic integration of modular precision automation, NMR/IR/MS/X‑ray analytics, and an AI‑ready FAIR data backbone to enable autonomous, 24/7 DMTA workflows and scalable QC/R&D operations.
Bruker (Nasdaq: BRKR, BRKRP) announced a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend will be paid on March 2, 2026 to holders of record as of February 15, 2026.